Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

Helena Earl Louise Hiller Anne-Laure Vallier Shrushma Loi Karen McAdam Luke Hughes-Davies Daniel W Rea Donna Howe Kerry Raynes Helen B Higgins Maggie Wilcox Chris Plummer Betania Mahler-Araujo Elena Provenzano Anita Chhabra Sophie Gasson Claire Balmer Jean E Abraham Carlos Caldas Peter S Hall Bethany Shinkins Christopher McCabe Claire T Hulme David Miles Andrew M WardleyDavid A CameronJanet A Dunn

Published in: Health technology assessment (Winchester, England) (2021)

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 40. See the NIHR Journals Library website for further project information.

Keyphrases

quality improvement
early breast cancer
public health
healthcare
health information
mental health
early stage
study protocol
health promotion
randomized controlled trial
clinical trial
social media
systematic review